Mayo Clinic, Scottsdale, AZ
Mitesh J. Borad , Sarah Lindsey Davis , Maeve Aine Lowery , Christine F. Lihou , Ghassan K. Abou-Alfa
Background: Dysregulation of fibroblast growth factor receptor (FGFR) signaling by FGFR translocations and activating mutations is implicated in many cancers, including CCA. FGFR2 translocation, the most common FGFRalteration, occurs in ~13% of pts with intrahepatic CCA. INCB054828 is a novel, orally available, selective inhibitor of FGFR1, FGFR2, and FGFR3 tyrosine kinase activity (AACR 2015; Abstract 771). Methods: This phase 2, open-label trial will evaluate INCB054828 monotherapy in pts with advanced/metastatic or unresectable CCA (NCT02924376). Pts will be prescreened locally or centrally for FGF/FGFR status prior to enrollment (Table): FGFR2 translocation (Cohort A); other FGF/FGFR alteration (Cohort B); no FGF/FGFR alteration (Cohort C; negative control for effects of FGF/FGFR alteration on objective response rate [ORR]). Eligibility criteria include: age ≥18 years; ECOG performance status ≤2; adequate liver and renal function; life expectancy ≥12 wks; disease progression after ≥1 prior systemic therapy; no prior use of selective FGFR inhibitors. Pts will self-administer INCB054828 orally at a starting dose of 13.5 mg QD on a 21-day cycle (2 wks on; 1 wk off); treatment will continue until disease progression or unacceptable toxicity. The primary endpoint will be ORR (complete or partial response, independent radiologic review committee, RECIST v1.1) in pts with FGFR2 translocation (Cohort A). Secondary endpoints include ORR in pts positive or negative for any FGF/FGFRalteration and duration of response, PFS, OS, and safety (all cohorts). The study has currently enrolled 2 pts (recruitment ongoing; estimated primary completion, April 2018). Clinical trial information: NCT02924376
Prescreen | FGFR2 translocation → cohort A (n≈60) Other FGF/FGFR alteration → cohort B (n≈20) No FGF/FGFR alteration → cohort C (n≈20) |
Screen, enroll and initiate INCB054828 | Oral QD dosing 21-day cycle (2 wks on; 1 wk off) |
Assessments start after cycle 2 | Stable disease/partial or complete response → continue treatment (restaging after cycle 4) Disease progression → discontinue treatment; safety and survival follow-up |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Guoming Shi
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Zachary Risch
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Milind M. Javle
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Shubham Pant